| Old Articles: <Older 6181-6190 Newer> |
|---|
 |
The Motley Fool
February 9, 2010
Brian Orelli |
Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status.   |
The Motley Fool
February 8, 2010
Brian Orelli |
An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement. |
BusinessWeek
February 4, 2010
Dermot Doherty |
The New Man at Novartis CEO Joe Jimenez says his consumer-products background, with stints at Clorox and Heinz, will be a booster for the drugmaker. |
Chemistry World
February 4, 2010
Matt Wilkinson |
More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets. |
The Motley Fool
February 4, 2010
Brian Orelli |
A Drugless Drugmaker IPO! Biotech investors embrace risk ... sort of. The most exciting thing about Ironwood's IPO? The company doesn't have any drugs on the market. |
The Motley Fool
February 4, 2010
Brian Orelli |
Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last? |
The Motley Fool
February 4, 2010
Brian Orelli |
Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct. |
The Motley Fool
February 3, 2010
Brian Orelli |
Wyeth Can't Save Pfizer Not much earnings growth, but the price is right. |
The Motley Fool
February 3, 2010
Brian Orelli |
Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease. |
InternetNews
February 2, 2010 |
UCSF Patients Latest Data Breach Victims A laptop containing the personal information of more than 4,300 patients receiving care at the University of California, San Francisco medical school was stolen in November. |
| <Older 6181-6190 Newer> Return to current articles. |
